

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/164680 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/551 (2006.01)
C07D 513/04 (2006.01) A61K 31/554 (2006.01)
C07D 471/04 (2006.01) A61P 35/00 (2006.01)
C07D 453/06 (2006.01) A61P 29/00 (2006.01)
C07F 9/6561 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2023/063318

(22) International Filing Date:

27 February 2023 (27.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,916 25 February 2022 (25.02.2022) US
63/337,428 02 May 2022 (02.05.2022) US

(71) Applicant: **RECLUDIX PHARMA, INC.** [US/US]: 222 Third Street, Suite 1320, Cambridge, MA 02142 (US).

(72) Inventors: **BIFULCO, Neil**; 15 Lillian Ave, Sudbury, MA 01776 (US). **BREGMAN, Howard**; 12 Howard St., Melrose, MA 02176 (US). **CIANCHETTA, Giovanni**; 82 Herrick Rd, Boxford, MA 01921 (US). **HODOUS, Brian**; 22 Lawrence Lane, Arlington, MA 02474 (US). **REZNIK, Samuel, K.**; 35 Walden St. Apt. 3F, Cambridge, MA 02140 (US). **TANG, Yong**; 6 Plover St, West Roxbury, MA 02132 (US). **TASKER, Andrew**; 277 Talbert Ave, Simi Valley, CA 93065 (US). **VASWANI, Rishi, G.**; 219 Lowell Street, Lexington, MA 02421 (US). **SICKMIER, Ernest, Allen**; 61 Hunting Rd, Needham, MA 02494 (US). **YEOMAN, John**; 215 Harvard St Unit 13, Medford, MA 02155 (US). **TIAN, Xia**; 931 Massachusetts Ave. #604, Cambridge, MA 02139 (US).

(74) Agent: **DEGRAZIA, Michael, J.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS



(I);

(57) Abstract: Provided are compounds of Formula (I); and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditions. Preferred compounds are 6-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4h-pyrrolo[2,1-d][1,5]thiazocine derivatives.

WO 2023/164680 A1